Phase III clinical trial - Gynécologie - Ovaires

Gynécologie - Ovaires
Ouvert depuis le: 10.17.2021
Site: Paris
Ouvert depuis le: 01.15.2021
Site: Saint-Cloud
Public cible
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Description de l'essai

This is a phase III, randomized, double-blinded, multi-center study to assess the efficacy of the addition of atezolizumab to platinum-based doublet chemotherapy followed by maintenance niraparib in patients with recurrent high grade serous or endometriod epithelial ovarian, peritoneal, or tubal cancers, who have remained progression-free for at least 6 months since completion of their last treatment with platinum-based chemotherapy (TFIp > 6 months).;Approximately 414 patients will be randomized using an Interactive